Category Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Lu-177 PSMA Therapy Shows Promise in Early-Stage Prostate Cancer: LUNAR Trial Dosimetry Analysis

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.

A secondary analysis of the LUNAR trial reveals that neoadjuvant 177Lu-PSMA-I&T delivers well-tolerated radiation doses while significantly improving progression-free survival in patients with low-volume oligometastatic prostate cancer when combined with stereotactic radiotherapy. Background Oligometastatic prostate cancer—disease with limited metastatic spread—presents…